GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Bioray Biotech Co Ltd (ROCO:7561) » Definitions » EBIT

Bioray Biotech Co (ROCO:7561) EBIT : NT$-18.1 Mil (TTM As of Jun. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Bioray Biotech Co EBIT?

Bioray Biotech Co's earnings before interest and taxes (EBIT) for the six months ended in Jun. 2024 was NT$-11.7 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2024 was NT$-18.1 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Bioray Biotech Co's annualized ROC % for the quarter that ended in Jun. 2024 was -6.62%. Bioray Biotech Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was -6.76%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Bioray Biotech Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was -3.39%.


Bioray Biotech Co EBIT Historical Data

The historical data trend for Bioray Biotech Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bioray Biotech Co EBIT Chart

Bioray Biotech Co Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial 22.83 -0.28 -5.22 2.05 -12.87

Bioray Biotech Co Semi-Annual Data
Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.95 0.10 -6.53 -6.34 -11.72

Competitive Comparison of Bioray Biotech Co's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Bioray Biotech Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bioray Biotech Co's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bioray Biotech Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Bioray Biotech Co's EV-to-EBIT falls into.



Bioray Biotech Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$-18.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bioray Biotech Co  (ROCO:7561) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Bioray Biotech Co's annualized ROC % for the quarter that ended in Jun. 2024 is calculated as:

ROC % (Q: Jun. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Jun. 2024 ))/ count )
=-32.404 * ( 1 - 18.12% )/( (421.284 + 380.832)/ 2 )
=-26.5323952/401.058
=-6.62 %

where

Invested Capital(Q: Jun. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=550.062 - 28.684 - ( 140.546 - max(0, 87.028 - 292.452+140.546))
=380.832

Note: The Operating Income data used here is two times the semi-annual (Jun. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Bioray Biotech Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Jun. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Jun. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-23.442/( ( (310.992 + max(68.315, 0)) + (239.203 + max(74.591, 0)) )/ 2 )
=-23.442/( ( 379.307 + 313.794 )/ 2 )
=-23.442/346.5505
=-6.76 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(42.954 + 55.95 + 8.371) - (24.34 + 0 + 14.62)
=68.315

Working Capital(Q: Jun. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(43.63 + 57.385 + 15.915) - (28.684 + 0 + 13.655)
=74.591

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Bioray Biotech Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Jun. 2024 )
=-18.064/532.357
=-3.39 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bioray Biotech Co EBIT Related Terms

Thank you for viewing the detailed overview of Bioray Biotech Co's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Bioray Biotech Co Business Description

Traded in Other Exchanges
N/A
Address
No. 21-3, Shennong East Road, Changzhi Township, Pingtung County, Pingtung City, TWN, 90846
Bioray Biotech Co Ltd is engaged in the development and manufacturing of biological agents, including functional probiotics, medicinal fungi, and immune cell preparations. The company provides capsules, powders, lozenges, and liquids for Skincare, Anti-aging and anti-inflammatory, Silver Hair Maintenance, and Microbe and mineral supplement among others.

Bioray Biotech Co Headlines

No Headlines